Tern updates on Sure Ventures’ £1.52 million sale of Getvisibility

Tern Plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has noted that Sure Ventures PLC, a company in which Tern currently holds 2.7% of the equity, has announced that the disposal of Visibility Blockchain Limited (Getvisibility) is expected to generate a gross cash inflow to Sure Ventures of £1.52 million upon its completion, extracts of which are set out below.

Extracts from the Sure Ventures announcement:

Sure Ventures PLC, which invests in early-stage software companies in the rapidly growing technology areas of Artificial Intelligence, Augmented Reality, Virtual Reality and the Internet of Things, has announced that Sure Valley Ventures ICAV (Fund 1) has sold its entire position in Visibility Blockchain Limited (Getvisibility) in a cash sale to Forcepoint.

Getvisibility is a cybersecurity company focusing on data visibility and control and uses state-of-the-art artificial intelligence (“AI”) to classify and secure unstructured information and Forcepoint are a global leader in data and cloud security. The sale price will remain an undisclosed amount (the “Disposal”). However, the Disposal is expected to generate a gross cash inflow to Sure Ventures PLC of £1.52m.

The sale of Getvisibility would represent a c.4.5x multiple on SVV 1’s total investment. As at the 31 December 2024, the carrying value of the Sure Valley Ventures direct investment in Getvisibility was 7.024 million euros (on an unaudited basis). The sale of Getvisibility has been legally agreed by all parties but is subject to the satisfaction of certain conditions that are customary for a transaction of this type.

Sure Ventures PLC will use this cash inflow to pay down the debt drawn from its loan facility, ensure sufficient working capital is in place to continue its strategy and then look to pay a dividend to shareholders. This will be in line with the expert tax advice sought and rules relating to its investment trust tax status.

Gareth Burchell, a Director of Sure Ventures PLC, said: “This is an excellent result for Sure Ventures PLC and its shareholders. We would like to congratulate the Sure Valley Ventures team, the founders of Getvisibility and all connected with the execution of this sale. The proceeds will be used to clear down our debt, keep cash to avoid shareholder dilution and then pay a dividend to shareholders which the board will announce in due course.

Importantly, the message we wish to send shareholders is that SVV Fund 1 is now in “exit mode” and now we have cleared our debt and made provision for the future, any further exits will see increased returns by way of  further dividends”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search